|1.66 -0.34 (-17%)||12-01 16:00|
|Targets||6-month :||2.5||1-year :||3.83|
|Resists||First :||2.14||Second :||3.27|
|Supports||First :||0.3||Second :||0.25|
|MAs||MA(5) :||1.96||MA(20) :||0.73|
|MA(100) :||0.82||MA(250) :||3.37|
|MACD||MACD :||0.3||Signal :||0.1|
|%K %D||K(14,3) :||63||D(3) :||73.4|
|52-week||High :||11.52||Low :||0.25|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed below upper band by 26.9%. Bollinger Bands are 485% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||1.89 - 1.9||1.9 - 1.91|
|Low:||1.56 - 1.57||1.57 - 1.58|
|Close:||1.64 - 1.66||1.66 - 1.67|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Drug Manufacturers—Specialty & Generic
|Shares Out||11 (M)|
|Shares Float||1,110 (M)|
|Held by Insiders||4.3 (%)|
|Held by Institutions||11.1 (%)|
|Shares Short||294 (K)|
|Shares Short P.Month||17 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.09|
|Profit Margin||32.3 %|
|Operating Margin||-245.5 %|
|Return on Assets (ttm)||-17.2 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||-90.2 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||3.22|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-26 (M)|
|Levered Free Cash Flow||-39 (M)|
|Price to Book value||1.52|
|Price to Sales||0.51|
|Price to Cash Flow||-0.71|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|